These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1783363)

  • 1. Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects.
    Flouvat B; Roux A; Leneveu A; Prinseau J; Alexandre JA
    Fundam Clin Pharmacol; 1991; 5(8):741-52. PubMed ID: 1783363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative study of pharmacokinetics and effects on urinary secretion of electrolytes of furosemide and furosemide-amiloride in healthy subjects].
    Kantelip JP; Aiache JM; Beyssac E; Abella ML
    Therapie; 1991; 46(6):475-9. PubMed ID: 1819153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination and pharmacokinetics of a furosemide-amiloride drug combination.
    Jankowski A; Skorek-Jankowska A; Lamparczyk H
    J Chromatogr B Biomed Sci Appl; 1997 Jun; 693(2):383-91. PubMed ID: 9210443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of urinary kallikrein excretion to urinary potassium excretion during furosemide administration with and without amiloride.
    Obika LF
    Arch Int Physiol Biochim; 1987 Mar; 95(1):13-8. PubMed ID: 2441670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of single doses of a 20 mg frusemide/2.5 mg amiloride combination, 20 mg frusemide and placebo on plasma and urine electrolytes in healthy men.
    Warrington SJ; Sinclair AJ; Johnston A
    J Int Med Res; 1990; 18 Suppl 2():3B-9B. PubMed ID: 2361567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of furosemide in rats.
    Kang MJ; Yoon WH; Kim ON; Lee MG
    J Clin Pharm Ther; 1995 Feb; 20(1):13-21. PubMed ID: 7775609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
    Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
    J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary electrolyte excretion after frusemide, amiloride and a combination of these drugs: an open, crossover study.
    Hamdy RC; Vinson ME; Robbins AD; Struthers LP; Chapman SF; Norris RJ; Shaw HL
    Curr Med Res Opin; 1984; 9(2):124-31. PubMed ID: 6399888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amiloride blocks the onset of ACTH-induced hypertension in the sheep.
    Reid AF; Coghlan JP; Whitworth JA; Scoggins BA
    Am J Hypertens; 1990 Oct; 3(10):775-81. PubMed ID: 2171563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of the kaluretic properties of furosemide by triamterene (Dyrenium) in healthy volunteers.
    Levinson B; Shenouda M; Stypinski D
    Int J Clin Pharmacol Ther; 2005 Feb; 43(2):92-100. PubMed ID: 15726878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent reduction in renal magnesium clearance by amiloride during frusemide-induced diuresis in rats.
    Devane J; Ryan MP
    Br J Pharmacol; 1983 Nov; 80(3):421-8. PubMed ID: 6640198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius).
    Ali BH; Wong YC; Alhadrami GA; Charles BG; Bashir AK
    Res Vet Sci; 1998; 64(1):69-72. PubMed ID: 9557809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The separate modes and sites of action of furosemide and amiloride.
    Knauf H; Schollmeyer P; Steinhardt HJ
    Clin Nephrol; 1975; 3(4):148-52. PubMed ID: 238780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
    Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
    J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
    Matthesen SK; Larsen T; Vase H; Lauridsen TG; Jensen JM; Pedersen EB
    Clin Exp Hypertens; 2013; 35(5):313-24. PubMed ID: 22966789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of an oral frusemide/amiloride combination tablet.
    Brooks SG; Christie RB; Roche J; Fairhead AP; Muirhead D; Townsend HA; Shaw HL
    Curr Med Res Opin; 1984; 9(2):141-6. PubMed ID: 6399890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects.
    Abou-Auda HS
    Int J Clin Pharmacol Ther; 1998 May; 36(5):275-81. PubMed ID: 9629992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.
    Loew D; Barkow D; Schuster O; Knoell HE
    Eur J Clin Pharmacol; 1984; 26(2):191-5. PubMed ID: 6723757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.